James E. Hosch
Directeur/Membre du Conseil chez Arrogene, Inc.
Profil
James E.
Hosch is currently a Director at Arrogene, Inc. He was previously a Managing Director at WestPark Capital, Inc. He obtained an undergraduate degree from Texas A&M University.
Postes actifs de James E. Hosch
| Sociétés | Poste | Début |
|---|---|---|
Arrogene, Inc.
 Arrogene, Inc. Pharmaceuticals: MajorHealth Technology Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA. | Directeur/Membre du Conseil | 13/05/2016 |
Anciens postes connus de James E. Hosch
| Sociétés | Poste | Fin |
|---|---|---|
WestPark Capital, Inc.
 WestPark Capital, Inc. Investment ManagersFinance WestPark Capital, Inc. (WPC) is a SEC-registered investment advisor headquartered in Los Angeles, California. The firm was founded by Richard Rappaport in 1999 and is a subsidiary of Westpark Capital Group LLC. WPC offers investment services to individual and institutional investors. | Gestionnaire de Portefeuille-Actions | - |
Formation de James E. Hosch
| Texas A&M University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
WestPark Capital, Inc.
WestPark Capital, Inc. Investment ManagersFinance WestPark Capital, Inc. (WPC) is a SEC-registered investment advisor headquartered in Los Angeles, California. The firm was founded by Richard Rappaport in 1999 and is a subsidiary of Westpark Capital Group LLC. WPC offers investment services to individual and institutional investors. | Finance |
Arrogene, Inc.
Arrogene, Inc. Pharmaceuticals: MajorHealth Technology Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA. | Health Technology |
